MOCCI, IGNAZIA MARIA CONSOLATA
MOCCI, IGNAZIA MARIA CONSOLATA
FARMACOLOGIA TRASLAZIONALE - IFT
Neuroprotective Effects of the Nutraceutical Dehydrozingerone and Its C2-Symmetric Dimer in a Drosophila Model of Parkinson’s Disease
2024 Setzu, Maria Dolores; Mocci, Ignazia; Fabbri, Davide; Carta, Paola; Muroni, Patrizia; Diana, Andrea; Dettori, Maria Antonietta; Casu, Maria Antonietta
Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease.
2023 Angius, F; Mocci, I; Ercoli, T; Loy, F; Fadda, L; Palmas, Mf; Cannas, G; Manzin, A; Defazio, G; Carta, Ar.
Effects of memantine on mania-like phenotypes exhibited by Drosophila Shaker mutants
2023 Mocci, I; Casu, Ma; Sogos, V; Liscia, A; Angius, R; Cadeddu, F; Fanti, M; Muroni, P; Talani, G; Diana, A; Collu, M; Setzu, Md.
Improvements of Motor Performances in the Drosophila LRRK2 Loss-of-Function Model of Parkinson's Disease: Effects of Dialyzed Leucocyte Extracts from Human Serum
2020 Diana, A; Collu, M; Casu, Ma; Mocci, I; Aguilarsantelises, M; Setzu, Md
Modeling Parkinson's disease neuropathology and symptoms by intranigral inoculation of preformed human ?-synuclein oligomers
2020 Boi L.; Pisanu A.; Palmas M.F.; Fusco G.; Carboni E.; Casu M.A.; Satta V.; Scherma M.; Janda E.; Mocci I.; Mulas G.; Ena A.; Spiga S.; Fadda P.; De Simone A.; Carta A.R.
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2(WD40) Genetic Model of Parkinson's Disease.
2020 Casu, Ma; Mocci, I; Isola, R; Pisanu, A; Boi, L; Mulas, G; Greig, Nh; Setzu, Md; Carta, Ar
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G?(i/o) protein inhibitor
2018 Porcu, A; Melis, M; Turecek, R; Ullrich, C; Mocci, I; Bettler, B; Gessa, Gl; Castelli, Mp
In vitro disaggregation and dissolution of four IR Lamotrigine solid dosage forms
2015 Manca, Ilaria; Manca, Ilaria; Pettinau, Francesca; Mocci, Ignazia; M Usai, Elisabetta; Pittau, Barbara
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Neuroprotective Effects of the Nutraceutical Dehydrozingerone and Its C2-Symmetric Dimer in a Drosophila Model of Parkinson’s Disease | 1-gen-2024 | Setzu, Maria Dolores; Mocci, Ignazia; Fabbri, Davide; Carta, Paola; Muroni, Patrizia; Diana, Andrea; Dettori, Maria Antonietta; Casu, Maria Antonietta | |
Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease. | 1-gen-2023 | Angius, F; Mocci, I; Ercoli, T; Loy, F; Fadda, L; Palmas, Mf; Cannas, G; Manzin, A; Defazio, G; Carta, Ar. | |
Effects of memantine on mania-like phenotypes exhibited by Drosophila Shaker mutants | 1-gen-2023 | Mocci, I; Casu, Ma; Sogos, V; Liscia, A; Angius, R; Cadeddu, F; Fanti, M; Muroni, P; Talani, G; Diana, A; Collu, M; Setzu, Md. | |
Improvements of Motor Performances in the Drosophila LRRK2 Loss-of-Function Model of Parkinson's Disease: Effects of Dialyzed Leucocyte Extracts from Human Serum | 1-gen-2020 | Diana, A; Collu, M; Casu, Ma; Mocci, I; Aguilarsantelises, M; Setzu, Md | |
Modeling Parkinson's disease neuropathology and symptoms by intranigral inoculation of preformed human ?-synuclein oligomers | 1-gen-2020 | Boi L.; Pisanu A.; Palmas M.F.; Fusco G.; Carboni E.; Casu M.A.; Satta V.; Scherma M.; Janda E.; Mocci I.; Mulas G.; Ena A.; Spiga S.; Fadda P.; De Simone A.; Carta A.R. | |
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2(WD40) Genetic Model of Parkinson's Disease. | 1-gen-2020 | Casu, Ma; Mocci, I; Isola, R; Pisanu, A; Boi, L; Mulas, G; Greig, Nh; Setzu, Md; Carta, Ar | |
Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a G?(i/o) protein inhibitor | 1-gen-2018 | Porcu, A; Melis, M; Turecek, R; Ullrich, C; Mocci, I; Bettler, B; Gessa, Gl; Castelli, Mp | |
In vitro disaggregation and dissolution of four IR Lamotrigine solid dosage forms | 1-gen-2015 | Manca, Ilaria; Manca, Ilaria; Pettinau, Francesca; Mocci, Ignazia; M Usai, Elisabetta; Pittau, Barbara |